Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK's Neuroscience Centre of Excellence for Drug Discovery.

Autifony Therapeutics: researching treatments for hearing disorders – tinnitus & age related hearing loss - & schizophrenia. Running clinical trials now

The company's main focus is the discovery and development of new pharmaceutical treatments for hearing disorders, such as age related hearing loss, and for other serious central nervous system disorders such as schizophrenia. 

The company is privately funded by leading venture capital investors. Autifony’s head office is at the Imperial College Incubator in London, and it has a subsidiary with medicinal chemistry and biology labs based in Verona, Italy.